Carol Cherkis, PhD


Life Sciences Expert Consultant

President, BioInfoStrategies

Practice Areas: Strategic Alliances, Business Development, M&A, , Corporate Equity Investments.

Carol has 25+ years experience business management & consulting, with a diverse global client base including government agencies, start ups, established companies, & Fortune 100 firms. Her practice encompasses a wide variety of health/biotechnology areas, including drug discovery, bio instrumentation, medical devices, diagnostics, agriculture, food preservation, & bio remediation.

Carol’s areas of business expertise include: strategic alliance formation, business development, competitive intelligence & strategic planning, organizational development, technology assessment & licensing, project management, & product development.

For the last few years she has focused on formation of alliances with companies in China, Japan, Canada, & Brazil.

Besides consulting for  Silicon Valley Nano Ventures Dr. Cherkis is the President of Bio Info Strategies, a consulting firm she founded after a 20 year multi functional career with The Dow Chemical Company.  Her advisory services focus on assisting small and medium-sized, fast growing companies in the biotechnology/ pharmaceutical, medical device, diagnostics, healthcare-IT, biochemical reagents, biodetectnology/ instrumentation, and bio-derived chemicals/biomaterials areas.

Projects include the commercial feasibility of technologies, developing & implementing of business strategies, and establishing licensing, co-development, marketing, and distribution alliances.

Carol’s clients include:  the Nomura Research Institute for Japan’s METI; Nitto Denko, a long-lived, Japanese chemicals, materials, and opto/biosensors public company; the US National Cancer Institute’s Bioinformatics Center; a mid-stage Chinese regenerative medicine company (GrandeHopeBio); the Alberta, Canada government’s International Business Partnering Program (Calgary Scientific, D-Tex); a US-based distributor of food safety & water quality test instruments in China (TN Technologies); Teijin, a major, public Japanese company interested in bio  materials & high-value chemicals produced from biomass; as well as a publicly-listed US manufacturer/global supplier of chemical/biological purification & analytical systems (Bio-Rad).

Her other activities have included:

Member, Board of Directors; Salient Pharmaceuticals, Inc., an early-stage, Houston, Texas based company developing treatments for a variety of gastrointestinal conditions.

Proposal Reviewer: Life Sciences & Healthcare for the National Research Council of the U.S. National Academy of Sciences and for I-Corps@Ohio, Ohio state’s initiative to foster entrepreneurship.

Vice President of Business Development; GNI Group Ltd., a Japanese/Chinese Pharmaceutical Company that went public on the Tokyo Stock Exchange (2160) in 2007.

Director of Healthcare at Frost & Sullivan, a well-known, global market research company.

Biotechnology Program Director, The Corporate Ventures Group, The Dow Chemical Company

Scientist, Market Manager, Business Development Manager, The Dow Chemical Company

Education: A.B. Biology, Bryn Mawr College; Ph.D. Biological Chemistry, University of Michigan Medical School.